Robert C. Goeltz II, Chief Financial Officer at Arcus Biosciences, Inc. (RCUS), sold 2,004 shares at $20.00 ($40K) on 2024-01-02, disclosed to the SEC on 2024-01-04.
Scheduled sale ($40k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| RCUS | SELL | 2025-12-18 | $557K | — | Filing → |
| RCUS | SELL | 2025-11-26 | $125K | — | Filing → |
| RCUS | SELL | 2025-10-29 | $100K | — | Filing → |